Substituted Azabicyclo[2.2.1]heptanes as Selective Orexin‑1 Antagonists: Discovery of JNJ-54717793

The orexin system consists of two neuropeptides (orexin-A and orexin-B) that exert their mode of action on two receptors (orexin-1 and orexin-2). While the role of the orexin-2 receptor is established as an important modulator of sleep wake states, the role of the orexin-1 receptor is believed to pl...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:ACS medicinal chemistry letters 2020-10, Vol.11 (10), p.2002-2009
Hauptverfasser: Préville, Cathy, Bonaventure, Pascal, Koudriakova, Tatiana, Lord, Brian, Nepomuceno, Diane, Rizzolio, Michele, Mani, Neelakandha, Coe, Kevin J, Ndifor, Anthony, Dugovic, Christine, Dvorak, Curt A, Coate, Heather, Pippel, Daniel J, Fitzgerald, Anne, Allison, Brett, Lovenberg, Timothy W, Carruthers, Nicholas I, Shireman, Brock T
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:The orexin system consists of two neuropeptides (orexin-A and orexin-B) that exert their mode of action on two receptors (orexin-1 and orexin-2). While the role of the orexin-2 receptor is established as an important modulator of sleep wake states, the role of the orexin-1 receptor is believed to play a role in addiction, panic, or anxiety. In this manuscript, we describe the optimization of a nonselective substituted azabicyclo[2.2.1]­heptane dual orexin receptor antagonist (DORA) into orally bioavailable, brain penetrating, selective orexin-1 receptor (OX1R) antagonists. This resulted in the discovery of our first candidate for clinical development, JNJ-54717793.
ISSN:1948-5875
1948-5875
DOI:10.1021/acsmedchemlett.0c00085